Medtronic Reports Q3 GAAP EPS Decline Amid Restructuring & Faces $1.1B+ Antitrust Verdict

summarizeSummary

Medtronic plc reported an 11.9% decline in Q3 GAAP diluted EPS, driven by increased tariffs and restructuring charges, despite strong revenue growth. The company also faces a significant potential liability from a $382 million antitrust jury verdict, which could be trebled.

check_boxKey Events

• Q3 GAAP EPS Decline

  Diluted EPS decreased by 11.9% to $0.89 for the quarter, contrasting with earlier positive non-GAAP guidance, primarily due to increased tariffs and restructuring charges.

• Significant Antitrust Verdict

  A jury awarded $382 million in damages in an antitrust lawsuit, which will be trebled, creating a potential liability exceeding $1.1 billion. Medtronic plans to appeal the verdict.

• Increased Restructuring Charges

  The company incurred $172 million in restructuring charges for the quarter, including $84 million in asset write-offs, partly related to the planned Diabetes business separation.

• Strong Revenue Growth

  Net sales for the quarter increased by 8.7% to $9.017 billion, driven by growth across most businesses and favorable currency impacts.

auto_awesomeAnalysis

This 10-Q provides the full financial details for the third quarter of fiscal year 2026, adding crucial context to the preliminary "strong financial results" announced in the 8-K on February 17, 2026. While net sales increased by 8.7% for the quarter, GAAP diluted EPS decreased by 11.9% year-over-year. This decline was primarily attributed to higher costs from tariffs on imported goods and $172 million in restructuring charges, including $84 million in asset write-offs related to terminating a manufacturing agreement in the Diabetes unit. The most significant new development is a jury verdict against Medtronic in an antitrust lawsuit, awarding $382 million in damages, which will be automatically trebled to over $1.1 billion. Although Medtronic plans to challenge this verdict and has not yet accrued a liability, this represents a substantial potential financial risk. On a positive note, the company announced its intent to acquire CathWorks Ltd. for up to $585 million, expanding its Cardiovascular portfolio, and the U.S. Supreme Court ruled President Trump's tariff policies unconstitutional, which could alleviate future cost pressures.